HETEROGENEITY OF THE EFFECT OF COMBINED FRACTIONATED RADIOTHERAPY AND EGFR/HER2 TYROSINE KINASE INHIBITION

被引：0
作者：
Gurtner, K. [1 ,2 ]
Schuetze, C. [1 ,2 ]
Soica, F. [3 ]
Baumann, M. [1 ,2 ]
Krause, M. [1 ,2 ]
机构：
[1] Tech Univ, Dept Radiat Oncol, OncoRay Ctr Radiat Res Oncol, Fac Med, Dresden, Germany
[2] Tech Univ, Dept Radiat Oncol, OncoRay Ctr Radiat Res Oncol, Univ Hosp Carl Gustav Carus, Dresden, Germany
[3] Boehringer Ingelheim Austria, Vienna, Austria
来源：
RADIOTHERAPY AND ONCOLOGY | 2008年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
128
引用
收藏
页码：S42 / S43
页数：2
相关论文
共 50 条
  • [21] HER2 heterogeneity
    Prat, A.
    BREAST, 2021, 56 : S4 - S4
  • [22] New dual inhibitors of EGFR and HER2 protein tyrosine kinases
    Fink, BE
    Vite, GD
    Mastalerz, H
    Kadow, JF
    Kim, SH
    Leavitt, KJ
    Du, K
    Crews, D
    Wong, TW
    Hunt, JT
    Vyas, DM
    Tokarski, JS
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (21) : 4774 - 4779
  • [23] The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches
    Zaczek, A
    Brandt, B
    Bielawski, KP
    HISTOLOGY AND HISTOPATHOLOGY, 2005, 20 (03) : 1005 - 1015
  • [24] BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor for cancer therapy.
    Solca, F
    Baum, A
    Guth, B
    Colbatzky, F
    Blech, S
    Amelsberg, A
    Himmelsbach, F
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9025S - 9025S
  • [25] TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2
    Chouitar, J.
    Vincent, S.
    Brake, R.
    Li, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S811 - S811
  • [26] Pyrrolotriazine dual EGFR/HER2 protein tyrosine kinase inhibitors with solubilizing groups at C-5
    Mastalerz, Harold
    Chang, Ming
    Chen, Ping
    Cook, Donald
    Dextraze, Pierre
    Fink, Brian E.
    Gavai, Ashvinikumar
    Goyal, Bindu
    Han, Wen-Ching
    Johnson, Walter
    Kim, Soong-Hoon
    Langley, David
    Lee, Francis
    Leavitt, Kenneth
    Norris, Derek
    Marathe, Punit
    Mathur, Arvind
    Oppenheimer, Simone
    Ruediger, Edward
    Tarrant, James
    Tokarski, John
    Vite, Gregory
    Vyas, Dolatrai
    Wong, Henry
    Wong, Tai
    Zhang, Hongjian
    Zhang, Guifen
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 806 - 806
  • [27] Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition
    Yano, S
    Kondo, K
    Yamaguchi, M
    Richmond, G
    Hutchison, M
    Wakeling, A
    Averbuch, S
    Wadsworth, P
    ANTICANCER RESEARCH, 2003, 23 (5A) : 3639 - 3650
  • [28] BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaive patients with adenocarcinoma of the lung and activating EGFR mutations
    Yang Chih-Hsin
    Shih Jin-Yuan
    Su Wu-Chou
    Hsia Te-Chun
    Ho Ching-Liang
    Dudek, Arkadiusz Z.
    Terlizzi, Elizabeth
    Zhao Yihua M
    Shahidi, Mehdi
    Miller, Vincent A.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S294 - S295
  • [29] Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition
    Yen, Hsin-Yung
    Liu, Ying-Chih
    Chen, Nai-Yu
    Tsai, Chia-Feng
    Wang, Yi-Ting
    Chen, Yu-Ju
    Hsu, Tsui-Ling
    Yang, Pan-Chyr
    Wong, Chi-Huey
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (22) : 6955 - 6960
  • [30] Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
    Meedendorp, Arenda D.
    ter Elst, Arja
    't Hart, Nils A.
    Groen, Harry J. M.
    Schuuring, Ed
    van der Wekken, Anthonie J.
    FRONTIERS IN ONCOLOGY, 2018, 8
12345